Compare Amphastar Pharmaceuticals Inc (AMPH) vs WD 40 Company (WDFC) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

WDFC stock trades at $264.91, up 10.65% ($25.49) on strong Q2 2026 earnings that beat estimates with EPS of $2.33 versus $1.58 expected. The technical outlook is bullish with support at $237 and resistance at $245. Fundamentals show robust revenue growth to $675M in 2026 and a net income margin of 13.22%, though valuation multiples like a P/E of 40.28 appear elevated. Positive media coverage highlights the company's strong brand and consistent performance.

The outlook remains positive given earnings beats and brand strength, but high valuation and margin pressure from input costs pose risks. Analyst consensus is mostly neutral with 71% hold ratings, suggesting cautious optimism. The stock offers stability but may face headwinds if growth slows or costs rise further.